Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-11-13 23:22Core Viewpoint - The company, Nocare Biopharma, reported significant growth in revenue and improvements in gross margin for the first nine months of 2025, driven by the sales of its core product, Obatuzumab, and a licensing agreement with Prolium Bioscience Inc [2][3]. Financial Performance - Total revenue for the first nine months of 2025 reached 1.115 billion RMB, representing a year-on-year increase of 59.85% [2]. - The gross margin improved to 88.8%, up from 86.0% in the same period last year, an increase of 2.8 percentage points [2]. - The net loss for the same period was 72 million RMB, a reduction of 74.78% compared to the previous year [2]. Product Performance - Sales revenue from the core product, Obatuzumab, amounted to 1.010 billion RMB in the first nine months of 2025, marking a year-on-year growth of 45.77% [3]. - In April 2025, Obatuzumab received approval for a new indication for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients [3]. - Obatuzumab is the first and only BTK inhibitor approved in China for the MZL indication and has been included in multiple recommendations in the latest CSCO lymphoma treatment guidelines [3]. Cash Position - As of September 30, 2025, the company held approximately 7.759 billion RMB in cash and cash equivalents, which supports the acceleration of its pipeline projects [4].